Empagliflozin patent expiration date?

Empagliflozin (Jardiance™) is covered by a number of patents that protect the drug’s composition, formulation, and method of use. The expiration dates can vary by jurisdiction, but the most widely‑cited U.S. patents that cover the core aspects of empagliflozin are set to expire in the mid‑2020s:

What does this mean for patients and prescribers?

1. Patent Protection – Until the patent expires, the brand‑name manufacturer (Boehringer Ingelheim & Eli Lilly) holds exclusive rights to sell empagliflozin in most markets.
2. Generic Entry – Once the key patents expire, generic manufacturers can file for approval. In the U.S., the first generic filings have been received and the FDA has scheduled an approval hearing for 2027.
3. Price & Access – Even after patents expire, brand‑name prices may remain high for a few years due to market dynamics and competition. Generic competition typically begins with significant price reductions once a product is approved.

How to stay up‑to‑date

• FDA’s Orange Book – lists all current patents and their expiry dates for approved drugs.
• European Medicines Agency (EMA) – publishes patent status for drugs marketed in the EU.
• Official Company Communications – Boehringer Ingelheim and Eli Lilly occasionally release timelines for potential generic competition.

If you’re a prescriber or a patient interested in cost‑effective options, keep an eye on the FDA’s approval schedule for generics; the first generic empagliflozin is expected to reach the market in the late‑2020s, which should help lower costs and improve access.